National Biotechnology Coordination Initiative

Summary#

This bill would create a National Biotechnology Initiative to coordinate how the federal government supports, regulates, and safeguards biotechnology. It would set up a new National Biotechnology Coordination Office in the Executive Office of the President and require dozens of agencies to work together on research, data, commercialization, regulation, workforce, and security. The broad goal is to improve U.S. security, economic productivity, and global competitiveness in biotechnology.

Key changes:

• Creates an Interagency Committee and a National Biotechnology Coordination Office led by a Director who advises the President on biotech.
• Requires participating agencies to coordinate on research, biological data, commercialization, biosafety/biosecurity, workforce development, public information, and international engagement.
• Orders a public website with plain-language resources, a regulatory “dashboard,” a repository of decisions and interagency agreements, a Q&A feature, and a digital single-application portal for biotech products regulated by multiple agencies.
• Mandates an annual report and a comprehensive national biotechnology strategy every five years, including a national biological data strategy and a competitiveness assessment.
• Requires a plan for regulatory streamlining within one year; if agencies cannot agree on a clear regulatory pathway, the Office of Management and Budget (OMB) must step in to resolve overlaps and gaps.
• Authorizes funding to staff and run the Coordination Office and sets a 20-year timeline before the Office transitions into a smaller secretariat role.

What it means for you#

• Businesses developing biotech products

  • Expect clearer, more predictable regulatory pathways, including for products regulators consider well understood; a plan for streamlining is due within one year.
  • A future single-application digital portal could reduce duplicative filings when multiple agencies regulate a product.
  • Potentially more support for testing, scale‑up, and commercialization (testbeds, access to user facilities, use of SBIR/STTR), and possible incentives to retool industrial sites.
  • More coordinated export and trade diplomacy aimed at market access and international standards.
  • Greater focus on cybersecurity and protection of biological data and infrastructure, with increased information sharing on threats.

• Researchers and universities

  • Continued and coordinated funding for biotech R&D, instrumentation, standards, and interdisciplinary centers.
  • Growth in biological data resources, standardization, and tools (including AI) to analyze data.
  • Emphasis on ethical, legal, and social implications research and on public understanding.
  • Expanded access to high‑performance computing and federal facilities; potential collaboration through national testbeds.

• Workers and students

  • New and expanded training programs, curricula, fellowships, and re‑/up‑skilling opportunities (including for veterans and industry workers).
  • A national framework to define biotech jobs and skills could clarify career paths and credentials.

• Federal employees and agencies

  • Each participating agency must name a senior lead for biotech, coordinate activities with the new Office, and join interagency subcommittees.
  • New fellowships allow staff to rotate across agencies to learn biotech work elsewhere.
  • Regular reporting and strategy development will add planning and data‑tracking duties.

• General public

  • A centralized website will offer plain‑language biotech information and a way to ask questions and get a coordinated federal response.
  • The bill seeks regular public outreach (workshops, educational events) to gather input on benefits and risks.

• International partners and markets

  • The government would step up regulatory and commercial diplomacy, pursue data‑sharing agreements and talent exchanges, and work on aligned export controls and international standards.

Expenses#

Estimated public cost: at least $132 million over FY2026–FY2030 for the Coordination Office. Additional agency costs are likely, but no estimate is available.

• Authorized to the National Science Foundation (to support the Office): $22M (FY2026), $35M (FY2027), $25M each year (FY2028–FY2030).
• Agencies are directed to support expanded activities (R&D, data infrastructure, testbeds, workforce, regulatory work, international engagement); the bill does not provide specific appropriations for these, and no total cost estimate is provided.
• Building and maintaining the coordinated website, repositories, and single-application portal will require IT spending and staff time across agencies; no estimate is provided.
• The Comptroller General (GAO) must review and report periodically; no specific cost estimate is provided.

Proponents' View#

• The bill appears intended to reduce duplication and improve coordination across many agencies so biotech research, regulation, and commercialization move faster and more efficiently.
• Clear, risk‑proportionate regulatory pathways and a single‑application portal could lower barriers and uncertainty for companies, especially for products regulators already understand well.
• Treating biological data as strategic infrastructure, with standards and security, could speed discovery and enable advanced computing and AI in biotech.
• Support for testbeds, user facilities, and small business programs could help firms scale up and manufacture in the United States, strengthening economic competitiveness.
• Stronger biosafety, biosecurity, cybersecurity, and counterintelligence efforts could better guard against misuse and protect sensitive data and infrastructure.
• Workforce and public bioliteracy efforts could build the talent pipeline and improve informed public discussion of benefits and risks.

Opponents' View#

• One concern is that centralizing coordination in a White House office and giving OMB a role in setting regulatory pathways may reduce agency independence or expert judgment in complex safety reviews.
• Efforts to “streamline” could be seen as risking weaker safety or environmental oversight if not carefully implemented; the bill does not detail how “risk‑proportionate” standards will be applied in practice.
• The bill assigns many new activities to agencies without dedicated funding beyond the coordination office, raising the possibility of unfunded mandates or diversion from existing programs.
• Consolidating biological data resources and creating a shared application portal may raise privacy and security questions; many protections are left to future strategies, standards, and guidance.
• Creating a new office, committee, reports, and strategies adds bureaucracy and reporting burdens that could slow decisions if not well managed.
• Allowing the Office to accept voluntary and uncompensated services may raise questions about transparency and potential conflicts of interest unless clear safeguards are set.